Clinical Trials Logo

Thyroid Neoplasms clinical trials

View clinical trials related to Thyroid Neoplasms.

Filter by:

NCT ID: NCT05819593 Not yet recruiting - Clinical trials for Anaplastic Thyroid Cancer

Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences

Start date: May 2024
Phase:
Study type: Observational

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in anaplastic thyroid cancer clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with anaplastic thyroid cancer who may be invited to participate in clinical research in the years to come.

NCT ID: NCT05758025 Not yet recruiting - Thyroid Cancer Clinical Trials

A New Surgical Strategy to Protect the Inferior Parathyroid

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The incidence of temporary hypoparathyroidism after thyroid surgery is 14%-60%, and the incidence of permanent hypoparathyroidism is 4%-11%. The protection of parathyroids has always been the focus and difficulty of thyroid surgery. The anatomical position of the superior parathyroids is relatively fixed, and can be preserved in situ easily; while the anatomical position of inferior parathyroids varies greatly between patients. It is always difficult to look for, identify, and protect them. Concepts such as thyro-thymic ligament and "thymus-vascular-inferior parathyroid plane" were raised to help identify the inferior parathyroids. We found that this surgical strategy can protect inferior parathyroids in situ effectively in our retrospective studies. Thus, we are going to carry out a prospective study to compare the new method and the traditional method of thyroidectomy, to see if more inferior parathyroids can be protected in situ through the new surgical strategy.

NCT ID: NCT05699590 Not yet recruiting - Clinical trials for Galactin 3-thyroid Carcinoma

Galectin-3 in Papillary Thyroid Carcinoma

Start date: March 2023
Phase:
Study type: Observational

Thyroid cancer is a common head and neck malignancy. It is the most common endocrine tumor in the body accounting for 1% of all cancers worldwide. The incidence of thyroid cancer varies worldwide. Most countries have reported an upward trend in its incidence. Thyroid cancer encompass the most common well-differentiated papillary carcinoma (80% of all thyroid cancers) and follicular carcinoma (15%), as well as poorly differentiated carcinoma (< 1%) and anaplastic carcinoma (< 2%). Papillary thyroid carcinomas (PTCs) are the most commonly encountered thyroid malignancies. The diagnosis of PTC is based on the special nuclear features such as overlapping of nuclei, intranuclear inclusions, optical clearing, anisonucleosis and nuclear grooves. However, it is often difficult to differentiate PTC from benign papillary thyroid hyperplasia . As differentiation between benign or malignant thyroid lesions has clinical, therapeutic, and prognostic significance, it is necessary to make accurate diagnosis by using biomarkers. Recently, a large number of immunohistochemical (IHC) markers have been studied to assist in differentiating non-neoplastic lesions from malignant thyroid lesions. CK19, galectin-3, TG, Ki67, BRAF, calcitonin, HBME-1, TTF-1, and RET are some of the examples of these IHC markers. Galectin-3 is a 31-kDa β-galactoside binding lectin. It has been shown to be expressed by several types of non-neoplastic and neoplastic cells, and it is involved in cell-cell adhesion and in cell-matrix interactions.

NCT ID: NCT05532384 Not yet recruiting - Thyroid Tumor Clinical Trials

Effect of Early Postoperative Drinking Water on Postoperative Recovery Quality of Patients With Thyroid Surgery

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This study is a single-center, prospective and randomized controlled study to investigate the effects of early recovery of oral intake (E) and late recovery of oral intake (L) on postoperative recovery quality and satisfaction of patients undergoing thyroid surgery. The study's primary outcome is quality of recovery-15 scale (Qor-15).

NCT ID: NCT05510934 Not yet recruiting - Clinical trials for Low Risk Differentiated Thyroid Cancer

Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.

Start date: September 30, 2022
Phase:
Study type: Observational

This study aims to assess the feasibility of a shared-care model for low-risk differentiated thyroid cancer (DTC) patients, primary care practitioners (PCPs) and the tertiary care center utilizing a digital health-based thyroid cancer assessment reminder system (TCARS) in Medable with an expedited referral to specialists for rapid assessment in case of a concern of recurrence.

NCT ID: NCT05468554 Not yet recruiting - Thyroid Cancer Clinical Trials

Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer

METHYR
Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer

NCT ID: NCT05466812 Not yet recruiting - Bone Metastases Clinical Trials

Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Start date: July 13, 2022
Phase: Phase 4
Study type: Interventional

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

NCT ID: NCT05446441 Not yet recruiting - Thyroid Cancer Clinical Trials

Endoscopic Thyroidectomy Versus Open Thyroidectomy for Papillary Thyroid Carcinoma

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

Recently, endoscopic thyroidectomy using gasless unilateral transaxillary approach has been proven feasible and safe in several Chinese medical centers. This study is aimed to compare multi-institutional Chinese outcomes of endoscopic thyroidectomy using gasless unilateral transaxillary approach and conventional open surgery.

NCT ID: NCT05428371 Not yet recruiting - Thyroid Cancer Clinical Trials

Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features

THYOMICS
Start date: January 1, 2023
Phase:
Study type: Observational

Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.

NCT ID: NCT05323669 Not yet recruiting - Thyroid Cancer Clinical Trials

Molecular Profile of Thyroid Nodules

MPTN
Start date: April 11, 2022
Phase:
Study type: Observational

Profiling and comparative analysis of genomic alterations and miRNA expression in benign and malignant thyroid tumors using histological and cytological specimens will be performed. Obtained information is necessary to create a molecular test to refine the cancer risk of cytologically indeterminate thyroid nodules.